Literature DB >> 28867189

Modified high-throughput quantification of plasma microRNAs in heparinized patients with coronary artery disease using heparinase.

Sufang Li1, Feng Zhang1, Yuxia Cui1, Manyan Wu1, Chongyou Lee1, Junxian Song1, Chengfu Cao1, Hong Chen2.   

Abstract

Heparin, a widely used anticoagulant in cardiovascular diseases, is notorious for its inhibitory effect on qRT-PCR-based detection. Heparinase I could degrade heparin in RNA. qRT-PCR-based TaqMan Low Density Array (TLDA) technology is commonly used for circulating microRNAs (miRNAs) profiling analysis. However, the effect of heparin contamination on inhibition of miRNAs TLDA amplification, as well as the method for removing heparin during this process, are not yet well investigated. We obtained the plasma RNA samples from patients undergoing percutaneous coronary intervention (PCI) before and after heparinization (n = 26). We found that heparin suppressed the miRNAs amplification by ∼8 cycles in the TLDA assay, which was absolutely reversed after treating the RNA samples with heparinase I using the components from TLDA reverse transcription system. We further observed that heparin inhibited the miRNAs amplification by ∼4 cycles in the qRT-PCR assay, which was also reversed by heparinase I using the similar method. Furthermore, we demonstrated that plasma miR-92a and miR-155 were differentially expressed in the patients undergoing PCI tested by TLDA assay, which was validated by qRT-PCR. In conclusion, we present a simple method for the removal of heparin with heparinase I, and for the subsequent successful miRNAs TLDA or RT-qPCR amplification.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coronary artery disease; Heparin; Heparinase; PCR; TLDA; microRNAs

Mesh:

Substances:

Year:  2017        PMID: 28867189     DOI: 10.1016/j.bbrc.2017.08.153

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Peripheral blood microRNAs and the COVID-19 patient: methodological considerations, technical challenges and practice points.

Authors:  Lucía Pinilla; Ivan D Benitez; Jessica González; Gerard Torres; Ferran Barbé; David de Gonzalo-Calvo
Journal:  RNA Biol       Date:  2021-02-15       Impact factor: 4.652

2.  MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction.

Authors:  Shengjue Xiao; Tongneng Xue; Qinyuan Pan; Yue Hu; Qi Wu; Qiaozhi Liu; Xiaotong Wang; Ailin Liu; Jie Liu; Hong Zhu; Yufei Zhou; Defeng Pan
Journal:  Cardiovasc Ther       Date:  2021-10-25       Impact factor: 3.023

Review 3.  Challenges in Using Circulating Micro-RNAs as Biomarkers for Cardiovascular Diseases.

Authors:  Kyriacos Felekkis; Christos Papaneophytou
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.